Your browser doesn't support javascript.
loading
Immunogenicity of the DNA/Protein Combined Vaccine against COVID-19.
Borgoyakova, M B; Karpenko, L I; Merkulyeva, I A; Shcherbakov, D N; Rudometov, A P; Starostina, E V; Shanshin, D V; Isaeva, A A; Nesmeyanova, V S; Volkova, N V; Belenkaya, S V; Volosnikova, E A; Zadorozhny, A M; Orlova, L A; Zaykovskaya, A V; Pyankov, O V; Bazhan, S I; Ilyichev, A A.
Afiliação
  • Borgoyakova MB; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia. borgoyakova_mb@vector.nsc.ru.
  • Karpenko LI; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia.
  • Merkulyeva IA; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia.
  • Shcherbakov DN; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia.
  • Rudometov AP; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia.
  • Starostina EV; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia.
  • Shanshin DV; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia.
  • Isaeva AA; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia.
  • Nesmeyanova VS; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia.
  • Volkova NV; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia.
  • Belenkaya SV; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia.
  • Volosnikova EA; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia.
  • Zadorozhny AM; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia.
  • Orlova LA; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia.
  • Zaykovskaya AV; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia.
  • Pyankov OV; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia.
  • Bazhan SI; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia.
  • Ilyichev AA; State Research Center of Virology and Biotechnology "VECTOR", Federal Service for the Oversight of Consumer Protection and Welfare, Koltsovo, Novosibirsk region, Russia.
Bull Exp Biol Med ; 174(2): 246-249, 2022 Dec.
Article em En | MEDLINE | ID: mdl-36598669
ABSTRACT
During the COVID-19 pandemic, the development of prophylactic vaccines, including those based on new platforms, became highly relevant. One such platform is the creation of vaccines combining DNA and protein components in one construct. For the creation of DNA vaccine, we chose the full-length spike protein (S) of the SARS-CoV-2 virus and used the recombinant receptor-binding domain (RBD) of the S protein produced in CHO-K1 cells as a protein component. The immunogenicity of the developed combined vaccine and its individual components was compared and the contribution of each component to the induction of the immune response was analyzed. The combined DNA/protein vaccine possesses the advantages of both underlying approaches and is capable of inducing both humoral (similar to subunit vaccines) and cellular (similar to DNA vaccines) immunity.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas de DNA / COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas de DNA / COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article